[1]李亚竑,刘洋,林厚维.后尿道瓣膜相关尿源性生物标志物的研究进展[J].临床小儿外科杂志,2026,(04):391-395.[doi:10.3760/cma.j.cn101785-202409056]
　Li Yahong,Liu Yang,Lin Houwei.Recent advances in urinary biomarkers related to posterior urethral valves[J].Journal of Clinical Pediatric Surgery,2026,(04):391-395.[doi:10.3760/cma.j.cn101785-202409056]
点击复制

后尿道瓣膜相关尿源性生物标志物的研究进展

《临床小儿外科杂志》[ISSN:1671-6353/CN:43-1380/R] 卷: 期数: 2026年04 页码: 391-395 栏目: 综述 出版日期: 2026-04-28
Title:
Recent advances in urinary biomarkers related to posterior urethral valves
作者:
李亚竑1; 3;  刘洋2;  林厚维2; 3
1. 浙江中医药大学, 杭州 310000;
2. 上海交通大学医学院附属新华医院小儿泌尿外科, 上海 200092;
3. 嘉兴市妇幼保健院小儿外科, 嘉兴 314050
Author(s):
Li Yahong1; 3;  Liu Yang2;  Lin Houwei2; 3
1. Zhejiang Chinese Medical University, Hangzhou 310000, China;
2. Department of Pediatric Urology, Affiliated Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;
3. Department of Pediatric Surgery, Jiaxing Maternity and Child Health Care Hospital, Jiaxing 314050, China
关键词:
后尿道瓣膜; 尿道梗阻; 终末期肾病; 生物标志物;  尿; 预测
Keywords:
Posterior Urethral Valve; Urethral Obstruction; End-stage Renal Disease; Biomarker; Urine; Prediction
DOI:
10.3760/cma.j.cn101785-202409056
摘要:
后尿道瓣膜是导致男性下尿路梗阻的常见病因,即使在婴幼儿时期切除后尿道瓣膜,部分患儿仍可能进展为终末期肾病。目前,临床上尚无可靠的生物标志物预测患儿是否会进展至终末期肾病。尿源性生物标志物较其他标志物更易且可更早被检测到,可能成为后尿道瓣膜患者肾脏结局的早期诊断和预后标志物。本文综述近年来后尿道瓣膜相关尿源性生物标志物的研究进展,以加深临床对于后尿道瓣膜疾病的认识。
Abstract:
Posterior urethral valve (PUV) is a common cause of lower urinary tract obstruction in boys.Despite valve ablation in early childhood,some patients may progress to end-stage renal disease (ESRD).Currently no reliable biomarkers are available in clinical practice for predicting the potential of developing ESRD.Detected more easily and earlier than other types,urinary-derived biomarkers may become early diagnostic and prognostic markers for renal outcomes in PUV children.This review focused upon the latest researches on urinary-derived biomarkers related to PUV,aiming to deepen the understanding of PUV.

参考文献/References:

[1] Tambo FFM, Tolefac PN, Ngowe MN, et al.Posterior urethral valves: 10 years audit of epidemiologic, diagnostic and therapeutic aspects in Yaoundé gynaeco-obstetric and paediatric hospital[J].BMC Urol, 2018, 18(1):46.DOI: 10.1186/s12894-018-0364-1.
[2] Matsell DG, Yu S, Morrison SJ.Antenatal determinants of long-term kidney outcome in boys with posterior urethral valves[J].Fetal Diagn Ther, 2016, 39(3): 214-221.DOI:10.1159/000439302.
[3] Klaus R, Lange-Sperandio B.Chronic kidney disease in boys with posterior urethral valves-pathogenesis, prognosis and management[J].Biomedicines, 2022, 10(8):1894.DOI:10.3390/biomedicines10081894.
[4] Bain A, Lavoie C, Rodriguez-Lopez S, et al.Renal outcomes of children born with posterior urethral valves at a tertiary center: a 15-year retrospective review[J].Can Urol Assoc J, 2023, 17(4):111-116.DOI:10.5489/cuaj.8102.
[5] Mehaffey E, Majid DSA.Tumor necrosis factor-α, kidney function, and hypertension[J].Am J Physiol Renal Physiol, 2017, 313(4):F1005-F1008.DOI: 10.1152/ajprenal.00535.2016.
[6] Misseri R, Meldrum DR, Dinarello CA, et al.TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling[J].Am J Physiol Renal Physiol, 2005, 288(2):F406-F411.DOI:10.1152/ajprenal.00099.2004.
[7] Meldrum KK, Misseri R, Metcalfe P, et al.TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction[J].Am J Physiol Regul Integr Comp Physiol, 2007, 292(4): R1456-R1464.DOI:10.1152/ajpregu.00620.2005.
[8] Chevalier RL.Obstructive nephropathy: towards biomarker discovery and gene therapy[J].Nat Clin Pract Nephrol, 2006, 2(3):157-168.DOI:10.1038/ncpneph0098.
[9] Vieira éLM, Pessoa Rocha N, Macedo Bastos F, et al.Posterior urethral valve in fetuses: evidence for the role of inflammatory molecules[J].Pediatr Nephrol, 2017, 32(8):1391-1400.DOI:10.1007/s00467-017-3614-7.
[10] Bhadoo D, Bajpai M, Panda SS.Posterior urethral valve: prognostic factors and renal outcome[J].J Indian Assoc Pediatr Surg, 2014, 19(3):133-137.DOI:10.4103/0971-9261.136459.
[11] Mandelia A, Bajpai M, Agarwala S, et al.The role of urinary TGF-β1, TNF-α, IL-6 and microalbuminuria for monitoring therapy in posterior urethral valves[J].Pediatr Nephrol, 2013, 28(10):1991-2001.DOI:10.1007/s00467-013-2506-8.
[12] Ma TT, Meng XM.TGF-β/Smad and renal fibrosis[J].Adv Exp Med Biol, 2019, 1165: 347-364.DOI:10.1007/978-981-13-8871-2_16.
[13] Ong CH, Tham CL, Harith HH, et al.TGF-β-induced fibrosis: a review on the underlying mechanism and potential therapeutic strategies[J].Eur J Pharmacol, 2021, 911:174510.DOI:10.1016/j.ejphar.2021.174510.
[14] Yang L, Besschetnova TY, Brooks CR, et al.Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury[J].Nat Med, 2010, 16(5):535-543.DOI:10.1038/nm.2144.
[15] Anand S, Bajpai M, Khanna T, et al.Urinary biomarkers as point-of-care tests for predicting progressive deterioration of kidney function in congenital anomalies of kidney and urinary tract: trefoil family factors (TFFs) as the emerging biomarkers[J].Pediatr Nephrol, 2021, 36(6):1465-1472.DOI:10.1007/s00467-020-04841-8.
[16] Kostic D, Dos Santos Beozzo GPN, do Couto SB, et al.First-year profile of biomarkers for early detection of renal injury in infants with congenital urinary tract obstruction[J].Pediatr Nephrol, 2019, 34(6):1117-1128.DOI:10.1007/s00467-019-4195-4.
[17] Panigrahi P, Chowdhary S, Sharma SP, et al.Role of urinary transforming growth factor beta-B1 and monocyte chemotactic protein-1 as prognostic biomarkers in posterior urethral valve[J].J Indian Assoc Pediatr Surg, 2020, 25(4):219-224.DOI: 10.4103/jiaps.jiaps_104_19.
[18] Sharma NK, Panda SS, Ratan SK, et al.Role of urinary biomarkers (transforming growth factor β1, neutrophil gelatinase-associated lipocalin, and cystatin C) as a prognostic factor of renal outcome in the posterior urethral valve[J].J Indian Assoc Pediatr Surg, 2024, 29(3):204-212.DOI:10.4103/jiaps.jiaps_210_23.
[19] Dewitte A, Villeneuve J, Lepreux S, et al.CD154 induces interleukin-6 secretion by kidney tubular epithelial cells under hypoxic conditions: inhibition by chloroquine[J].Mediators Inflamm, 2020, 2020:6357046.DOI:10.1155/2020/6357046.
[20] Rocha NP, Bastos FM, Vieira éLM, et al.The protective arm of the renin-angiotensin system may counteract the intense inflammatory process in fetuses with posterior urethral valves[J].J Pediatr (Rio J), 2019, 95(3):328-333.DOI:10.1016/j.jped.2018.02.003.
[21] Mittal PG, Samujh R, Peters NJ, et al.Correlation of urinary biomarkers (interleukin-6, transforming growth factor-β, E-Cadherin, and MCP-1) with conventional parameters of disease progression in patients of posterior urethral valves: a comparative analysis[J].J Indian Assoc Pediatr Surg, 2022, 27(5): 537-543.DOI:10.4103/jiaps.jiaps_182_21.
[22] Wright AE, Wragg R, Lopes J, et al.Prediction of need for intervention in posterior urethral valves: use of urine osmolality[J].J Pediatr Surg, 2018, 53(2): 316-320.DOI:10.1016/j.jpedsurg.2017.11.026.
[23] Dreux S, Rosenblatt J, Moussy-Durandy A, et al.Urine biochemistry to predict long-term outcomes in fetuses with posterior urethral valves[J].Prenat Diagn, 2018, 38(12):964-970.DOI:10.1002/pd.5359.
[24] Spaggiari E, Faure G, Dreux S, et al.Sequential fetal serum β2-microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction[J].Ultrasound Obstet Gynecol, 2017, 49(5):617-622.DOI:10.1002/uog.15968.
[25] Heikkil? J, Jahnukainen T, Holmberg C, et al.Association of renal glomerular and tubular function with renal outcome in patients with posterior urethral valves[J].Urology, 2021, 153:285-290.DOI:10.1016/j.urology.2020.11.045.
[26] Sharma S, Joshi M, Gupta DK, et al.Consensus on the management of posterior urethral valves from antenatal period to puberty[J].J Indian Assoc Pediatr Surg, 2019, 24(1):4-14.DOI:10.4103/jiaps.JIAPS_148_18.
[27] Chen YY, Liu SY, Wu LL, et al.Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory diseases[J].Cell Prolif, 2023, 56(7):e13428.DOI:10.1111/cpr.13428.
[28] Cianci R, Simeoni M, Cianci E, et al.Stem cells in kidney ischemia: from inflammation and fibrosis to renal tissue regeneration[J].Int J Mol Sci, 2023, 24(5):4631.DOI:10.3390/ijms24054631.
[29] Galipeau J.Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity[J].Stem Cells, 2021, 39(9):1145-1154.DOI:10.1002/stem.3380.
[30] Mohammadjafari H, Rafiei A, Mousavi SA, et al.Role of urinary levels of endothelin-1, monocyte chemotactic peptide-1, and N-acetyl glucosaminidase in predicting the severity of obstruction in hydronephrotic neonates[J].Korean J Urol, 2014, 55(10):670-676.DOI:10.4111/kju.2014.55.10.670.
[31] Pastore V, Bartoli F.Urinary excretion of EGF and MCP-1 in children with vesicoureteral reflux[J].Int Braz J Urol, 2017, 43(3):549-555.DOI:10.1590/s1677-5538.ibju.2015.0132.
[32] Trnka P, Hiatt MJ, Ivanova L, et al.Phenotypic transition of the collecting duct epithelium in congenital urinary tract obstruction[J].J Biomed Biotechnol, 2010, 2010:696034.DOI:10.1155/2010/696034.
[33] Trnka P, Ivanova L, Hiatt MJ, et al.Urinary biomarkers in obstructive nephropathy[J].Clin J Am Soc Nephrol, 2012, 7(10):1567-1575.DOI:10.2215/CJN.09640911.
[34] Rinnert M, Hinz M, Buhtz P, et al.Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine[J].Cell Tissue Res, 2010, 339(3):639-647.DOI:10.1007/s00441-009-0913-8.
[35] Busch M, Dünker N.Trefoil factor family peptides-friends or foes?[J].Biomol Concepts, 2015, 6(5/6):343-359.DOI:10.1515/bmc-2015-0020.
[36] Du TY, Luo HM, Qin HC, et al.Circulating serum trefoil factor 3(TFF3) is dramatically increased in chronic kidney disease[J].PLoS One, 2013, 8(11): e80271.DOI:10.1371/journal.pone.0080271.
[37] Yamanari T, Sugiyama H, Tanaka K, et al.Urine trefoil factors as prognostic biomarkers in chronic kidney disease[J].Biomed Res Int, 2018, 2018:3024698.DOI:10.1155/2018/3024698.
[38] Lebherz-Eichinger D, Tudor B, Ankersmit HJ, et al.Trefoil factor 1 excretion is increased in early stages of chronic kidney disease[J].PLoS One, 2015, 10(9): e0138312.DOI:10.1371/journal.pone.0138312.
[39] Anand S, Bajpai M, Khanna T, et al.Influence of genetic polymorphism in renin-angiotensin system-candidate genes on urinary trefoil family factor 3 levels in children with congenital anomalies of kidney and urinary tract[J].Pediatr Nephrol, 2022, 37(1):139-145.DOI:10.1007/s00467-021-05160-2.
[40] Bastos FM, Leal CRV, Vaz de Castro PAS, et al.Tubular and glomerular biomarkers of renal tissue function in the urine of fetuses with posterior urethral valves[J].J Pediatr Urol, 2022, 18(3):368.e1-368.e9.DOI:10.1016/j.jpurol.2022.03.019.
[41] Mischak H, Delles C, Vlahou A, et al.Proteomic biomarkers in kidney disease: issues in development and implementation[J].Nat Rev Nephrol, 2015, 11(4): 221-232.DOI:10.1038/nrneph.2014.247.
[42] Klein J, Bascands JL, Mischak H, et al.The role of urinary peptidomics in kidney disease research[J].Kidney Int, 2016, 89(3):539-545.DOI:10.1016/j.kint.2015.10.010.
[43] Schanstra JP, Zürbig P, Alkhalaf A, et al.Diagnosis and prediction of CKD progression by assessment of urinary peptides[J].J Am Soc Nephrol, 2015, 26(8): 1999-2010.DOI:10.1681/ASN.2014050423.
[44] Klein J, Lacroix C, Caubet C, et al.Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV)[J].Sci Transl Med, 2013, 5(198):198ra106.DOI:10.1126/scitranslmed.3005807.
[45] Buffin-Meyer B, Klein J, Breuil B, et al.Combination of the fetal urinary metabolome and peptidome for the prediction of postnatal renal outcome in fetuses with PUV[J].J Proteomics, 2018, 184:1-9.DOI:10.1016/j.jprot.2018.06.012.
[46] Buffin-Meyer B, Tkaczyk M, Stańczyk M, et al.A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves[J].Pediatr Nephrol, 2020, 35(3):469-475.DOI:10.1007/s00467-019-04390-9.
[47] Buffin-Meyer B, Klein J, van der Zanden LFM, et al.The ANTENATAL multicentre study to predict postnatal renal outcome in fetuses with posterior urethral valves: objectives and design[J].Clin Kidney J, 2020, 13(3):371-379.DOI:10.1093/ckj/sfz107.>

相似文献/References:

[1]李佳,威力江·赛买提,帕洛克·迪力木拉提,等.钬激光治疗后尿道瓣膜疾病的疗效评价[J].临床小儿外科杂志,2017,16(04):399.
[2]李洁,王衍泽,杜国强,等.尿道下裂行尿道板纵切卷管尿道成形术后尿道梗阻的危险因素分析[J].临床小儿外科杂志,2026,(02):153.[doi:10.3760/cma.j.cn101785-202509031]
　Li Jie,Wang Yanze,Du Guoqiang,et al.Risk factor analysis of urethral obstruction after tubularized incised plate urethroplasty for hypospadias[J].Journal of Clinical Pediatric Surgery,2026,(04):153.[doi:10.3760/cma.j.cn101785-202509031]

备注/Memo

收稿日期:2024-9-23。
基金项目:上海市市级医院诊疗技术推广及优化管理项目(SHDC22022306)
通讯作者:林厚维,Email:lhw@zjxu.edu.cn

更新日期/Last Update: 1900-01-01